AiCuris Receives Orphan Drug Designation for its Phase II Drug AIC246 for the Prevention of HCMV Disease

26-Apr-2011 - Germany

Wuppertal , Germany, April 21, 2011 / B3C newswire / - AiCuris announced today that AIC246, the Company’s inhibitor against the human cytomegalovirus HCMV, currently undergoing phase IIb testing, has been granted Orphan Drug Designation for the prevention of HCMV disease. This decision was made by the European Commission following the positive opinion released by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).

“We are very pleased to have received Orphan Drug status for AIC246. This decision by the authorities confirms our view that this innovative drug will be of significant benefit to those at risk of developing HCMV disease which is a very serious and life-threatening condition. The Orphan Drug status will also support AiCuris in the development of AIC246 as it gives easier access to scientific support by the agencies, e.g. by advice during the product development phase” commented AiCuris CEO, Prof. Rübsamen-Schaeff.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances